 Jean-Baptiste Le Pichon
Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neurology | 7 | 2020 | 10 | 2.370 |
Why?
| | Awards and Prizes | 3 | 2019 | 4 | 1.940 |
Why?
| | Seizures | 6 | 2021 | 24 | 1.480 |
Why?
| | Pediatrics | 4 | 2020 | 183 | 1.380 |
Why?
| | Genetic Testing | 2 | 2021 | 86 | 1.240 |
Why?
| | Humans | 30 | 2024 | 6929 | 0.920 |
Why?
| | Genetic Predisposition to Disease | 4 | 2021 | 226 | 0.910 |
Why?
| | Drug Resistant Epilepsy | 2 | 2021 | 7 | 0.860 |
Why?
| | Nervous System Diseases | 3 | 2020 | 13 | 0.810 |
Why?
| | Hyperbilirubinemia, Neonatal | 2 | 2023 | 6 | 0.810 |
Why?
| | Muscle Hypotonia | 1 | 2021 | 7 | 0.800 |
Why?
| | Kernicterus | 2 | 2023 | 7 | 0.800 |
Why?
| | Homozygote | 2 | 2013 | 22 | 0.800 |
Why?
| | Genetic Association Studies | 1 | 2021 | 54 | 0.780 |
Why?
| | Intellectual Disability | 3 | 2024 | 34 | 0.770 |
Why?
| | Developmental Disabilities | 4 | 2017 | 42 | 0.730 |
Why?
| | Ketosis | 1 | 2019 | 2 | 0.680 |
Why?
| | Milk, Human | 1 | 2019 | 24 | 0.670 |
Why?
| | Periodicals as Topic | 1 | 2018 | 6 | 0.650 |
Why?
| | Chromosomes, Human, Pair 15 | 3 | 2013 | 5 | 0.580 |
Why?
| | Child | 15 | 2023 | 3348 | 0.500 |
Why?
| | Chromosome Deletion | 3 | 2013 | 21 | 0.500 |
Why?
| | Infant | 9 | 2023 | 1449 | 0.500 |
Why?
| | Genome, Human | 2 | 2014 | 84 | 0.450 |
Why?
| | Female | 12 | 2021 | 3534 | 0.450 |
Why?
| | Chromosome Disorders | 1 | 2013 | 7 | 0.440 |
Why?
| | Transcriptome | 1 | 2013 | 59 | 0.420 |
Why?
| | Mutation | 4 | 2021 | 213 | 0.410 |
Why?
| | Male | 14 | 2021 | 3367 | 0.400 |
Why?
| | TRPM Cation Channels | 1 | 2010 | 1 | 0.370 |
Why?
| | Alleles | 3 | 2024 | 213 | 0.370 |
Why?
| | Receptors, Nicotinic | 1 | 2010 | 8 | 0.370 |
Why?
| | Retrospective Studies | 4 | 2021 | 1337 | 0.330 |
Why?
| | Infant, Newborn | 3 | 2023 | 826 | 0.320 |
Why?
| | Bulbar Palsy, Progressive | 1 | 2017 | 1 | 0.290 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2017 | 1 | 0.290 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2017 | 3 | 0.290 |
Why?
| | Adolescent | 10 | 2021 | 2183 | 0.290 |
Why?
| | Treatment Outcome | 5 | 2021 | 649 | 0.280 |
Why?
| | Vagus Nerve Stimulation | 2 | 2021 | 6 | 0.240 |
Why?
| | Drosophila Proteins | 1 | 2024 | 8 | 0.240 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2022 | 100 | 0.240 |
Why?
| | Epilepsy | 2 | 2021 | 14 | 0.230 |
Why?
| | Bilirubin | 3 | 2023 | 25 | 0.230 |
Why?
| | Neurodevelopmental Disorders | 1 | 2024 | 23 | 0.230 |
Why?
| | Dystonia | 1 | 2023 | 8 | 0.230 |
Why?
| | Child, Preschool | 8 | 2021 | 1562 | 0.230 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2021 | 47 | 0.220 |
Why?
| | Phenotype | 2 | 2021 | 256 | 0.220 |
Why?
| | Comparative Genomic Hybridization | 3 | 2012 | 9 | 0.210 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 2 | 2013 | 2 | 0.200 |
Why?
| | Karyotyping | 1 | 2021 | 11 | 0.200 |
Why?
| | Amino Acid Substitution | 1 | 2021 | 12 | 0.200 |
Why?
| | Anticonvulsants | 2 | 2019 | 27 | 0.200 |
Why?
| | Rare Diseases | 1 | 2022 | 42 | 0.190 |
Why?
| | Lennox Gastaut Syndrome | 1 | 2021 | 2 | 0.190 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 44 | 0.190 |
Why?
| | Genomics | 1 | 2022 | 102 | 0.190 |
Why?
| | Neurosciences | 1 | 2020 | 1 | 0.180 |
Why?
| | Genotype | 1 | 2021 | 408 | 0.180 |
Why?
| | Genome | 2 | 2022 | 33 | 0.180 |
Why?
| | Return to Sport | 1 | 2019 | 2 | 0.180 |
Why?
| | Intracranial Hypertension | 1 | 2019 | 2 | 0.180 |
Why?
| | Post-Concussion Syndrome | 1 | 2019 | 2 | 0.180 |
Why?
| | Athletic Injuries | 1 | 2019 | 3 | 0.180 |
Why?
| | Rest | 1 | 2019 | 4 | 0.180 |
Why?
| | Trauma Severity Indices | 1 | 2019 | 15 | 0.170 |
Why?
| | Risk Reduction Behavior | 1 | 2019 | 10 | 0.170 |
Why?
| | Epilepsies, Partial | 1 | 2019 | 5 | 0.170 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 78 | 0.170 |
Why?
| | Referral and Consultation | 1 | 2019 | 32 | 0.170 |
Why?
| | Telemedicine | 1 | 2020 | 59 | 0.170 |
Why?
| | Internship and Residency | 1 | 2019 | 36 | 0.170 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2018 | 1 | 0.160 |
Why?
| | History, 21st Century | 1 | 2018 | 7 | 0.160 |
Why?
| | Publishing | 1 | 2018 | 8 | 0.160 |
Why?
| | Child Abuse | 1 | 2019 | 47 | 0.160 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 39 | 0.160 |
Why?
| | Pedigree | 2 | 2022 | 61 | 0.160 |
Why?
| | Adult | 5 | 2024 | 1199 | 0.160 |
Why?
| | Cohort Studies | 1 | 2019 | 281 | 0.160 |
Why?
| | Myoclonic Epilepsies, Progressive | 1 | 2017 | 2 | 0.150 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2017 | 8 | 0.150 |
Why?
| | Protein Folding | 1 | 2016 | 2 | 0.140 |
Why?
| | Microtubules | 1 | 2016 | 5 | 0.140 |
Why?
| | Microtubule-Associated Proteins | 1 | 2016 | 5 | 0.140 |
Why?
| | Tubulin | 1 | 2016 | 7 | 0.140 |
Why?
| | Brain Diseases | 1 | 2016 | 6 | 0.140 |
Why?
| | Risk Assessment | 1 | 2017 | 136 | 0.140 |
Why?
| | Animals | 5 | 2024 | 741 | 0.140 |
Why?
| | Group IV Phospholipases A2 | 1 | 2015 | 2 | 0.130 |
Why?
| | Mitochondria | 1 | 2015 | 10 | 0.130 |
Why?
| | Jaundice, Neonatal | 1 | 2014 | 1 | 0.130 |
Why?
| | Gait Ataxia | 1 | 2014 | 1 | 0.130 |
Why?
| | Hyperkinesis | 1 | 2014 | 2 | 0.130 |
Why?
| | Exome | 1 | 2014 | 37 | 0.120 |
Why?
| | Tourette Syndrome | 1 | 2014 | 6 | 0.120 |
Why?
| | Epilepsy, Absence | 1 | 2013 | 3 | 0.110 |
Why?
| | Electroencephalography | 1 | 2013 | 7 | 0.110 |
Why?
| | Attention | 1 | 2013 | 13 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 15 | 0.110 |
Why?
| | Congenital Abnormalities | 1 | 2012 | 17 | 0.110 |
Why?
| | RNA, Messenger | 1 | 2013 | 115 | 0.110 |
Why?
| | Case-Control Studies | 1 | 2013 | 216 | 0.110 |
Why?
| | Mental Disorders | 1 | 2012 | 16 | 0.110 |
Why?
| | Middle Aged | 2 | 2013 | 645 | 0.100 |
Why?
| | Aged | 1 | 2013 | 411 | 0.100 |
Why?
| | Microcephaly | 1 | 2010 | 5 | 0.090 |
Why?
| | Sequence Analysis, DNA | 2 | 2022 | 116 | 0.080 |
Why?
| | Membrane Transport Proteins | 1 | 2017 | 16 | 0.070 |
Why?
| | Disease Progression | 1 | 2017 | 110 | 0.070 |
Why?
| | Brain | 2 | 2017 | 79 | 0.070 |
Why?
| | Mice, Knockout | 2 | 2017 | 60 | 0.070 |
Why?
| | Mice | 2 | 2017 | 339 | 0.060 |
Why?
| | Animals, Genetically Modified | 1 | 2024 | 5 | 0.060 |
Why?
| | Drosophila | 1 | 2024 | 7 | 0.060 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2024 | 6 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2024 | 21 | 0.060 |
Why?
| | Nigeria | 1 | 2023 | 3 | 0.060 |
Why?
| | United States | 2 | 2020 | 670 | 0.060 |
Why?
| | Prospective Studies | 1 | 2023 | 547 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 47 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 37 | 0.040 |
Why?
| | Salivation | 1 | 2018 | 3 | 0.040 |
Why?
| | Protein Binding | 2 | 2016 | 31 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 37 | 0.040 |
Why?
| | NIH 3T3 Cells | 1 | 2017 | 5 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2017 | 32 | 0.040 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 90 | 0.040 |
Why?
| | Sulfasalazine | 1 | 1977 | 1 | 0.040 |
Why?
| | Spindle Apparatus | 1 | 2016 | 3 | 0.040 |
Why?
| | Molecular Chaperones | 1 | 2016 | 7 | 0.040 |
Why?
| | Crohn Disease | 1 | 1977 | 25 | 0.040 |
Why?
| | Age of Onset | 1 | 2016 | 28 | 0.040 |
Why?
| | Fibroblasts | 1 | 2016 | 26 | 0.040 |
Why?
| | Rats | 2 | 2014 | 112 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2016 | 58 | 0.040 |
Why?
| | Genetic Variation | 1 | 2017 | 166 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2015 | 17 | 0.030 |
Why?
| | Locomotion | 1 | 2014 | 2 | 0.030 |
Why?
| | Rats, Gunn | 1 | 2014 | 4 | 0.030 |
Why?
| | Calcium | 1 | 2015 | 40 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 43 | 0.030 |
Why?
| | Young Adult | 1 | 2017 | 641 | 0.030 |
Why?
| | Base Sequence | 1 | 2014 | 87 | 0.030 |
Why?
| | Health Care Costs | 1 | 2014 | 31 | 0.030 |
Why?
| | Time Factors | 2 | 2013 | 263 | 0.030 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2014 | 38 | 0.030 |
Why?
| | Family | 1 | 2014 | 27 | 0.030 |
Why?
| | Comorbidity | 1 | 2014 | 56 | 0.030 |
Why?
| | Age Factors | 1 | 2014 | 211 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2014 | 29 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2013 | 15 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2013 | 45 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 102 | 0.030 |
Why?
| | Chromosome Duplication | 1 | 2012 | 3 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2013 | 198 | 0.030 |
Why?
| | Temperance | 1 | 1990 | 1 | 0.020 |
Why?
| | Alcoholism | 1 | 1990 | 4 | 0.020 |
Why?
| | Cardiomyopathy, Dilated | 1 | 1990 | 9 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 45 | 0.020 |
Why?
| | Societies, Medical | 1 | 2010 | 50 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 104 | 0.020 |
Why?
| | Digitoxin | 1 | 1975 | 1 | 0.020 |
Why?
| | Threonine Dehydratase | 1 | 1975 | 1 | 0.020 |
Why?
| | Hydro-Lyases | 1 | 1975 | 2 | 0.020 |
Why?
| | Microsomes, Liver | 1 | 1975 | 45 | 0.020 |
Why?
| | Escherichia coli | 1 | 1975 | 29 | 0.020 |
Why?
| | Radionuclide Ventriculography | 1 | 1990 | 1 | 0.010 |
Why?
| | Electrocardiography | 1 | 1990 | 20 | 0.010 |
Why?
| | Heart Failure | 1 | 1990 | 14 | 0.010 |
Why?
| | Substance-Related Disorders | 1 | 1990 | 26 | 0.010 |
Why?
| | Echocardiography | 1 | 1990 | 93 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 1990 | 329 | 0.010 |
Why?
| | Digitoxigenin | 1 | 1975 | 1 | 0.000 |
Why?
| | NADP | 1 | 1975 | 2 | 0.000 |
Why?
| | Chromatography, Thin Layer | 1 | 1975 | 3 | 0.000 |
Why?
| | Hydroxylation | 1 | 1975 | 14 | 0.000 |
Why?
| | In Vitro Techniques | 1 | 1975 | 25 | 0.000 |
Why?
| | Allosteric Site | 1 | 1975 | 1 | 0.000 |
Why?
| | Allosteric Regulation | 1 | 1975 | 2 | 0.000 |
Why?
| | Adenosine Monophosphate | 1 | 1975 | 2 | 0.000 |
Why?
| | Kinetics | 1 | 1975 | 34 | 0.000 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1975 | 21 | 0.000 |
Why?
| | Binding Sites | 1 | 1975 | 27 | 0.000 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|